Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation
      Description

      This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.

      Conditions
      AXIN1 Gene MutationAPC Gene MutationSolid Tumor
      Talk to us